Gastrointestinal
Esophageal:
CIRB #H-31326/RTOG #R1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma (RT requirements not yet met)
Colon/Rectal:
IRB #H-29680/NSABP #P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
CIRB #H-30341/CTSU #C80702: A Phase III Trial of 6 vs 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
IRB #H-31787/MDACC #2009-0288 POWER:Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients
Hepatocellular:
CIRB #H-29546/ CTSU #C80802: Phase III Randomized Study of Sorafenib plus Doxorubicin vs Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
IRB #pending/ RTOG R1112: Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma (RT requirements not met)
Pancreas:
CIRB #H-29237/ RTOG #R0848: A Phase III Trial Evaluating Both Erlotinib And Chemoradiation As Adjuvant Treatment For Patients With Resected Head Of Pancreas Adenocarcinoma
